Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

The financial statements for the first half of 2019 reflect operating results of -€5.3 million, compared to -€6.8 million one year earlier due to decreased expenses relating to the end of the NEW-HOPE Phase IIb trial.

Read the press release

Leave a Reply

Your email address will not be published.